Momenta Pharmaceuticals (MNTA) PT Lowered to $16 at Barclays; 'More Conservative Stance on Eventual (Generic Copaxone 40mg) Market Share'

October 4, 2017 12:02 PM

Barclays lowered its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $16.00 (from $17.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found